Poolbeg Pharma, an infectious disease firm spun out from Irish vaccine research company Open Orphan, has been granted a patent by the US Patent and Trademark Office (USPTO).
The US patent is related to methods introduced by Poolbeg to treat hypercytokinaemia, a severe immune reaction in the body that causes the release of too many pro-inflammatory signalling molecules called cytokines into the blood.
This can occur due to viral infection, such as severe influenza, cancer or other autoimmune responses.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
